Searched for
CIPLA ACQUISITIONS STRATEGY
Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...
- Cipla shares in focus after deal to acquire Inzpera Healthsciences for Rs 111 croreCipla shares: Cipla has agreed to acquire a 100% stake in Inzpera Healthsciences, making it a wholly owned subsidiary, as part of its strat...
- Cipla eyes acquisitions, inorganic partnerships in US marketCipla plans acquisitions and inorganic partnerships in the US market while strengthening its presence in the domestic market. The company a...
- Why Torrent Pharma is ready to go ahead with the daunting Cipla dealAhmedabad-based Torrent Pharma is seeking financing for a deal with Indian pharmaceutical company Cipla. Torrent Pharma is interested in bu...
- Bain dials Dr Reddy's Laboratories to team up for joint Cipla bidPrivate equity firm Bain Capital has approached Indian pharmaceutical company Dr Reddy's Laboratories (DRL) to explore a joint bid for the ...
- Cipla to acquire South Africa-based Actor PharmaActor was founded in 2009 and has quickly grown to become the fifth largest privately owned OTC player in the South African market. Actor s...
- Cipla's subsidiary to acquire US-based Avenue Therapeutics for $ 215 millionAt the second stage, InvaGen or its affiliates will acquire the remaining shares of Avenue's common stock, for up to USD 180 million in the...
- Cipla divests animal health business in South Africa, sub-Saharan AfricaThe deal comes with a potential revision linked to FY17 performance along with customary adjustment (within the price band of 250 mn Rand a...
- Cipla registers 43.8% fall in Q1 net profit; global CEO Subhanu Saxena resignsConsolidated sales stood at Rs 3,500 crore, compared with Rs 3,760 crore in the year-ago quarter. ET Now poll had estimated sales of Rs 8,3...
- Cipla drug launches hold promise for FY17, grows in prescription businessGenerics sales in the US, launch of inhalers in the UK and a ramp up from its acquisitions are key positive factors to look forward to.
- Goal to make US contribute 20% to our business by 2020: Sudhanshu Priyadarshi, CiplaWe have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.
- Cipla's ratings unlikely to be impacted by US acquisitions: India RatingsIndia Ratings & Research today said Cipla's ratings are unlikely to be affected by the recent cash-rich acquisitions of two US-based compan...
- Inorganic approach to growth relatively risky, but Cipla's recent acquisitions look good: Vinay KhattarAt this particular point in time, it looks a sane decision on part of Cipla management to go on for these acquisitions, says Khattar.
- InvaGen, Exelan acquisition will give Cipla manufacturing plant, R&D base in USCipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...
- Cipla to acquire Brazil's Duomed Produtos for Rs 2.6 croreThe deal has the approval of Brazilian health authority (ANVISA) and other regulatory authorities to import and distribute pharmaceutical p...
- Pharma companies on a talent hunt to fill skills gapThe sector has slowed from its peak growth rate, the lure of expansion in the Rs 75,000-crore pharma market has kept companies looking for ...
- Cipla completes buyout of Cipla Medpro for Rs 2,707 croreCipla on Tuesday said it has completed the buyout process of South African pharma firm Cipla Medpro for an aggregate consideration of Rs 2,...
- Brokers’ Call: Espirito puts a buy on CiplaEspirito Santo Securities has given a ‘Buy’ rating on Cipla with a fair value of Rs 440.
- Cipla completes the Medpro deal, buys 100% stake in the South African companyThe total consideration payable by Cipla is approximately $ 512 million or ZAR 4.5 billion.
Load More
